medigraphic.com
ISSN 2448-8909 (Print)

2015, Number 4

<< Back Next >>

Med Crit 2015; 29 (4)

Prophylactic effect of pravastatin in the incidence of ventilator-associated pneumonia (VAP)

González AA, Rodríguez LL, Elizalde BCI, Delgado QCA, Román FA, Garrido GJR

Language: Spanish
References: 26
Page: 214-221
PDF size: 217.39 Kb.


ABSTRACT

Objective: To determine whether prophylactic pravastatin compared to placebo reduces the risk of ventilator-associated pneumonia (VAP).
Material and methods: A double-blind controlled clinical trial, was conducted at the Internal Medicine Service, Xoco General Hospital, Mexico City in 44 intubated patients who met the inclusion criteria and were randomly assigned to receive pravastatin 40 mg (or 10 mg in case of kidney failure) (n = 22) or placebo (n = 22). Groups were followed for 10 days or until the patient’s death.
Results: Fourteen (32.55%) of the 44 patients developed VAP, eight (36.3%) in the pravastatin group and 6 (28.7%) in the placebo group (p = 0.51). Overall mortality was 39% (17/44), and by treatment group, ocurred in 36.3% (8/22) patients in the pravastatin group and 42.8% (9/22) in the placebo group (p = 0.53).
Conclusions: No benefit of prophylactic administration of pravastatin in the incidence of VAP was observed. We consider necessary to investigate a possible beneficial effect of statins on survival of patients with established infection.


REFERENCES

  1. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.

  2. Consenso Mexicano de Diagnóstico y Tratamiento de la Neumonía. Neumonías: Un Consenso Nacional de Expertos. México: Dresde Editorial Médica; 2002.

  3. Chaires R, Palacios A. Neumonía asociada a la ventilación mecánica: cómo prevenirla y situación en México. Rev Asoc Mex Med Crit y Ter Int. 2013;27(3):138-145.

  4. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care. 2002;165:867-903.

  5. Su LX, Meng K, Zhang X. Diagnosing ventilator-associated pneumonia in critically ill patients with sepsis. Am J Crit Care. 2012;21:e110-e119. doi: 10.4037/ajcc2012732.

  6. Meduri GU. Diagnosis and differential diagnosis of ventilator-associated pneumonia. Clin Chest Med. 1995;16:61-93.

  7. Grap MJ, Munro CI, Unoki T. Ventilator associated pneumonia: the potential critical role of emergency medicine in prevention. J Emerg Med. 2012;42(3):353-362.

  8. Maheshwari V, Paioli D, Rothaar R, Hill NS. Utilization of noninvasive ventilation in acute care hospitals: a regional survey. Chest. 2006;129:1226-1233.

  9. Klompas M. Prevention of ventilator-associated pneumonia. Expert Rev Anti Infect Ther. 2010;8(7):791-800.

  10. Palomar M, Rodríguez P. Prevención de la infección nosocomial en pacientes críticos. Med Int. 2010;34(8):523-533.

  11. Schultz MJ, Haas LE. Antibiotics or probiotics as preventive measures against ventilator-associated pneumonia: literature review. Crit Care. 2011;15(1):R18. doi: 10.1186/cc9963.

  12. Pan HY, DeVault AR, Swites BJ, Whigan D, Ivashkiv E, Willard DA, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther. 1990;48:201-207.

  13. Joo SJ. Anti-inflammatory effects of statins beyond cholesterol lowering. Korean Circ J. 2012;42(9):592-594.

  14. Hauacuja F, Gómez M. Efectos de las estatinas más allá del colesterol. Rev Endocr y Nut. 2008;14(2):73-88.

  15. Mennicket S, Bravo M. Efectos pleiotrópicos de las estatinas. Rev Med Chile. 2008;136:775-782.

  16. Rohilla A, Rohilla S, Kumar A. Pleiotropic effects of statins: a boulevard to cardioprotection. Arab J Chem. 2011. doi: 10.1016/j.arabjc.2011.06.025.

  17. Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis. 2002;160:41-48.

  18. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.

  19. Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemother. 2008;61:362-364.

  20. Makris D, Manoulakas E, Komnos A. Effect of pravastatin on intensive care unit: open label, randomized study. Crit Care Med. 2011;39(11):2440-2446.

  21. Armitage J. The safety of statins in clinical practice. Lancet. 2007;370:1781-1790.

  22. Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine. 2005;84:377-385.

  23. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective pravastatin pooling (PPP) project. Circulation. 2002;105:2341-2346.

  24. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ. 2006;333(7576):999.

  25. Frost FJ, Petersen H, Tollestrup K, et al. Influenzae and COPD mortality protection as peliotropic, dose-depent effects of statins. Chest. 2007;131:1006-1012.

  26. Gunnar A, Beck R, Hammerich A. The impact of statin use on pneumonia risk and outcome: a combined population-based case-control and cohort study. Crit Care. 2012;16(4):R122. doi:10.1186/cc11418.




2020     |     www.medigraphic.com